Slide Shows & Poster Presentations

Date Description Author
2016-04-29 Bloom Burton & Co. Healthcare Investor Conference Various
2016-04-07 April 2016 Corporate Presentation Oncolytics Biotech Inc.
2016-02-08 Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference Oncolytics Biotech Inc.
2016-02-08 18th Annual BIO CEO & Investor Conference Oncolytics Biotech Inc.
2015-12-08 Reolysin® Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients Dr. D.W. Sborov
2015-09-25 Combination Carfilzomib and the Viral Oncolytic Agent REOLYSIN® in Patients with Relapsed Multiple Myeloma: A Pilot Study Investigating Viral Proliferation Dr. D.W. Sborov
2015-09-01 September 2015 Corporate Presentation Oncolytics Biotech Inc.
2015-08-27 Oncolytic Reovirus in Combination with Paclitaxel/Carboplatin in NSCLC Patients with Ras Activated Malignancies, Long Term Results Dr. Miguel A. Villalona-Calero
2015-08-12 Canaccord Genuity 35th Annual Growth Conference Dr. Brad Thompson
2015-07-06 Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma Mahalingam et al
2015-06-15 9th International Conference on Oncolytic Virus Therapeutics Collaborator Abstracts and Posters Various
2015-04-20 AACR 2015 Annual Meeting Collaborator Poster Presentations Various
2015-04-15 REOLYSIN® and Immune Therapy: Rationale for Combination Therapy Dr. Matt Coffey
2015-03-26 REOLYSIN® and Immune Checkpoint Inhibitors: Rationale for Combination Therapy Dr. Giovanni Selvaggi
2015-03-05 Synergistic Combination of Oncolytic Reovirus Type 3 (Dearing) and Radiotherapy in Melanoma is Mediated Through Enhanced Viral Replication and Mitochondrial Apoptotic Signalling. Harrington, et al.
2014-09-16 Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study Oncolytics Biotech®